Literature DB >> 34626431

Exercise-induced changes of vital signs in adults with sickle cell disease.

Solomon Johnson1, Victor R Gordeuk2, Roberto Machado3, J Simon R Gibbs4, Mariana Hildesheim1, Jane A Little5, Gregory J Kato1, Mark T Gladwin1, Mehdi Nouraie1.   

Abstract

The six-minute walk test (6MWT) has been used in patients with sickle cell disease (SCD), in conjunction with tricuspid regurgitant velocity (TRV) and plasma N-terminal pro-brain natriuretic peptide (NT-pro BNP), to assess risk of having pulmonary hypertension. Exercise-induced vital sign changes (VSCs) are predictors of clinical outcomes in other diseases. In this study, we assess the predictors and prognostic value of 6MWT VSC in adult SCD patients. Data from a multinational study of SCD patients (Treatment of Pulmonary Hypertension with Sildenafil: walk-PHaSST) were used to calculate the 6MWT VSC. Predictors of VSC were identified by a multivariable analysis, and a survival analysis was conducted by the Cox proportional hazard method. An increase in heart rate was observed in 90% of the 630 SCD adults, 77% of patients had an increase in systolic blood pressure (SBP), and 50% of patients had a decrease in oxygen saturation. TRV (odds ratio [OR] = 1.82, p = .020), absolute reticulocyte count (OR = 1.03, p < .001), and hemoglobin (OR = 0.99, p = .035) predicted oxygen desaturation ≥ 3% during the 6MWT. In the adjusted analysis, SBP increase during the 6MWT was associated with improved survival (hazards ratio = 0.3, 95% confidence interval: 0.1-0.8). Increases in heart rate and blood pressure, as well as oxygen desaturation, are common in adults with SCD during the 6MWT. VSC is associated with markers of anemia and TRV and can be used for risk stratification. Any increase in SBP during the 6MWT was associated with improved survival and may be indicative of a patient's ability to increase stroke volume.
© 2021 Wiley Periodicals LLC.

Entities:  

Mesh:

Year:  2021        PMID: 34626431      PMCID: PMC8616821          DOI: 10.1002/ajh.26369

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  45 in total

Review 1.  Cardiovascular complications and risk of death in sickle-cell disease.

Authors:  Mark T Gladwin
Journal:  Lancet       Date:  2016-06-18       Impact factor: 79.321

Review 2.  Treating sickle cell disease by targeting HbS polymerization.

Authors:  William A Eaton; H Franklin Bunn
Journal:  Blood       Date:  2017-04-06       Impact factor: 22.113

Review 3.  Cardiovascular complications in patients with sickle cell disease.

Authors:  Mark T Gladwin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom.

Authors:  Inês Zimbarra Cabrita; Abubakar Mohammed; Mark Layton; Sara Ghorashian; Annette Gilmore; Gavin Cho; Jo Howard; Kofi A Anie; Lynda Desforges; Paul Bassett; Julia Grapsa; Luke Howard; Gaia Mahalingam; David Dawson; Fausto J Pinto; Petros Nihoyannopoulos; Sally C Davies; J Simon R Gibbs
Journal:  Br J Haematol       Date:  2013-05-29       Impact factor: 6.998

5.  Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients.

Authors:  Andrew Campbell; Caterina P Minniti; Mehdi Nouraie; Manuel Arteta; Sohail Rana; Onyinye Onyekwere; Craig Sable; Gregory Ensing; Niti Dham; Lori Luchtman-Jones; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

6.  The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe.

Authors:  Mehdi Nouraie; Janet S Lee; Yingze Zhang; Tamir Kanias; Xuejun Zhao; Zeyu Xiong; Timothy B Oriss; Qilu Zeng; Gregory J Kato; J Simon R Gibbs; Mariana E Hildesheim; Vandana Sachdev; Robyn J Barst; Roberto F Machado; Kathryn L Hassell; Jane A Little; Dean E Schraufnagel; Lakshmanan Krishnamurti; Enrico Novelli; Reda E Girgis; Claudia R Morris; Erika Berman Rosenzweig; David B Badesch; Sophie Lanzkron; Oswaldo L Castro; Jonathan C Goldsmith; Victor R Gordeuk; Mark T Gladwin
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

7.  Factors associated with survival in a contemporary adult sickle cell disease cohort.

Authors:  Hany Elmariah; Melanie E Garrett; Laura M De Castro; Jude C Jonassaint; Kenneth I Ataga; James R Eckman; Allison E Ashley-Koch; Marilyn J Telen
Journal:  Am J Hematol       Date:  2014-02-21       Impact factor: 10.047

8.  Abnormal pulmonary function in adults with sickle cell anemia.

Authors:  Elizabeth S Klings; Diego F Wyszynski; Vikki G Nolan; Martin H Steinberg
Journal:  Am J Respir Crit Care Med       Date:  2006-03-23       Impact factor: 21.405

9.  Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom.

Authors:  Mark T Gladwin; Robyn J Barst; J Simon R Gibbs; Mariana Hildesheim; Vandana Sachdev; Mehdi Nouraie; Kathryn L Hassell; Jane A Little; Dean E Schraufnagel; Lakshmanan Krishnamurti; Enrico Novelli; Reda E Girgis; Claudia R Morris; Erika Berman Rosenzweig; David B Badesch; Sophie Lanzkron; Oswaldo L Castro; James G Taylor; Jonathan C Goldsmith; Gregory J Kato; Victor R Gordeuk; Roberto F Machado
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

Review 10.  Cardiovascular complications of sickle cell disease.

Authors:  Vandana Sachdev; Douglas R Rosing; Swee Lay Thein
Journal:  Trends Cardiovasc Med       Date:  2020-02-11       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.